Saved in this browser. Sign in to sync across devices.
Separate approval from new evidence: Specific long-acting injectable aripiprazole products, including ABILIFY MAINTENA, have FDA-approved indications for adult bipolar I maintenance monotherapy. This October 2026 paper is a new observational comparison, not a new FDA approval or randomized proof of superiority.
How was the study conducted?
Researchers used the TriNetX Global Collaborative Network to study people with bipolar disorder who began taking oral aripiprazole between 2017 and 2023. Those switching to a long-acting injection within one month were compared with those continuing oral medication. Statistical propensity-score matching produced two groups of 1,814, followed for an average of 1.6 years. No treatment was randomly assigned.
ALL-CAUSE HOSPITALIZATION
HR 0.77
The injectable group had a 23% lower adjusted relative hazard (95% CI 0.69–0.85). This included hospitalization for any cause, not specifically mania or depression.
EMERGENCY-DEPARTMENT VISITS
HR 0.88
There was a 12% lower adjusted relative hazard (95% CI 0.79–0.98). Hazard ratios are not personal probabilities or absolute risk reductions.
EXTRAPYRAMIDAL SYMPTOMS
HR 2.20
Movement-related adverse symptoms were more frequent with injections (95% CI 1.38–3.50). They can include stiffness, tremor or other movement problems.
OBESITY DIAGNOSES
HR 1.17
The injectable group had higher relative obesity risk (95% CI 1.06–1.29), supporting continued metabolic monitoring.
Does the injection cause fewer hospitalizations?
That has not been established by this comparison. Even careful matching cannot fully account for differences in treatment choice, adherence, symptom history, appointment access, family support or other factors not captured in health records. The study examined all-cause hospitalization, which is not a direct measure of preventing bipolar relapse. No statistically clear overall difference was identified for suicidal ideation or behavior or all-cause mortality; that is not proof of equivalent safety.
Who might discuss a long-acting option?
Some adults find daily medication difficult to manage and value a clinician-administered dosing schedule. Others prefer pills, fewer clinic visits or easier medication adjustments. Choice depends on personal preference, formulation-specific FDA indication, previous response, side effects, access and practical support. These findings do not establish an injection indication for children or adolescents.
Questions to bring to a psychiatrist
- Is this exact long-acting product approved for the patient's diagnosis, age and maintenance needs?
- How do daily-life goals, side effects and injection appointments compare with the existing plan?
- What monitoring will address weight, blood sugar, lipids, restlessness and movement symptoms?
- How should missed visits, injection initiation, insurance and medication access be managed?
- What changes in mood, functioning or safety would trigger a clinical review?
What to take away
This study helps inform conversations about an existing adult maintenance option. It does not justify starting, stopping or switching medication without the treating clinician. Psychiatric follow-up, sleep routines and individualized relapse planning remain important.
Original study, FDA labeling and care guidance
- Translational Psychiatry — original study (October 21, 2026) ↗
Peer-reviewed observational target-trial emulation, with matching and sensitivity analyses.
- FDA — ABILIFY MAINTENA prescribing information ↗
Approved adult bipolar I maintenance indication and formulation-specific precautions.
- NIMH — Bipolar disorder ↗
Current clinical treatment and shared-decision context.
Evidence checked October 22, 2026 · Educational editorial draft; independent clinical review pending. Not individualized medical advice.